导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -16.05% | 4134/4773 |
| 近一周 | -5.91% | 5322/5462 |
| 近一月 | -2.25% | 1218/5421 |
| 近一季 | -3.19% | 1367/5209 |
| 近半年 | -14.70% | 3935/4920 |
| 近一年 | -19.54% | 3918/4366 |
| 近两年 | 5.50% | 2830/2954 |
| 近三年 | -20.26% | 2159/2253 |
| 成立以来 | 56.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.24% 4072/4961 |
-15.84% 4704/5312 |
- - |
- - |
| 2025 | 3.53% 3115/4813 |
-3.22% 3028/3635 |
2.98% 1222/4076 |
4.14% 3695/4524 |
-0.25% 2440/4813 |
| 2024 | -0.72% 2126/3463 |
-4.84% 1776/2808 |
-5.93% 1821/3014 |
14.27% 2017/3129 |
-2.95% 2215/3463 |
| 2023 | -14.00% 1577/2656 |
3.98% 1080/2280 |
-10.12% 2088/2385 |
-2.06% 616/2515 |
-6.03% 1602/2655 |
| 2022 | -5.65% 121/2207 |
-8.88% 301/1919 |
5.19% 932/2016 |
-8.40% 197/2113 |
7.47% 307/2208 |
| 2021 | 22.58% 140/1822 |
-6.28% 992/1255 |
15.52% 223/1330 |
-0.03% 476/1466 |
13.25% 76/1822 |
| 2020 | - - |
- - |
- - |
20.21% 59/1164 |
11.02% 569/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 宏利消费红利指数A VS. 长安沪深300非周期A(740101) |